Global Blood Therapeutics Announces GBT440 Receives FDA Fast Track Designation for Sickle Cell Disease

By: via Benzinga
Global Blood Therapeutics (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.